CA Live w circleR 2018 v2


   CWR7912   CWR8095   CA Live DC 2018 Sponsors

Congratulations to Dr. John Elfar, representing Penn State College of Medicine,

Winner of the 2018 CureAccelerator Live!

On October 16, John Elfar, MD representing Penn State College of Medicine won Cures Within Reach's 2018 CureAccelerator Live! philanthropic pitch event. CureAccelerator Live! brings together stakeholders from pharma, biotech, academia, medicine, philanthropy and patient groups to showcase repurposing projects in need of funding. 

Held in partnership with ExL's Collaborations Addressing Vulnerable Populations Forum in Herndon, Virginia, attendees voted for the winning repurposing clinical trial. The 2018 CureAccelerator Live! event focused on Mid-Atlantic region institutions with projects using repurposed therapies to treat an unmet medical need.


Read the full Press Release here

See Photos here

CA logo graphic only

Meet the CureAccelerator Live! Finalists:


Akiva Cohen 9243

Akiva S. Cohen, PhD: Dietary Therapy for Concussion (click to see project summary)

Over 1.5 million people in the United States suffer a new traumatic brain injury (TBI) each year, often resulting in death or long-term disability. Even mild TBI (mTBI), a concussion, can lead to an array of long-lasting neurological impairments. An estimated 3.2 to 5 million Americans currently live with neurological disabilities resulting from TBI. Impacts to the head are common in football, soccer, lacrosse, hockey, rugby, and basketball and in pursuits such as horseback riding, cycling, roller-blading, and boxing among others. No concussion is without consequences. In the short-term, athletes’ cognitive and athletic performance may suffer. In the long term, concussions, and perhaps even sub-concussive blows, are thought to cause alterations in brain structures and functions that can lead to impaired cognitive functioning and neurobehavioral problems. Despite the prevalence of TBI, no therapy currently exists to treat the underlying causes of the cognitive impairments suffered by TBI patients. We have developed a dietary therapy that mitigates injury-induced pathologies.

CHOP logo 2018


ElfarJohn wc 11 2017 002

John Elfar, MD: Repurposing 4AP to Answer the Golden Question in Trauma Surgery (A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma) (click to see project summary)

When severe limb trauma causes paralysis, surgeons struggle to make treatment decisions because it is impossible to tell whether nerves are completely severed or still connected but not functioning. Tests can help assess muscle, skin, vessels, and bone but there are no early tests for the status of nerve tissue. Nerves control all movement and feeling in a limb and severed nerves require urgent surgery to reconnect the nerve ends for recovery to be possible. Unless we risk further injury and operate just to verify nerve continuity, we must wait weeks in sometimes pointless expectation of spontaneous recovery only to discover that the nerve was severed – by that time it is likely too late for a successful surgical approach. The ability to rapidly diagnose whether paralyzed limbs contain intact nerves could revolutionize treatment of severe limb trauma, and we propose solving this problem by using a clinically safe approved drug (4-aminopyridine) for the entirely new purpose of providing a single-dose test for nerve continuity in our trauma patients.

pennstatehershey USE THIS






Adam Kaplin, MD, PhD: Repurposing a High-Blood Pressure Drug to Decrease Pediatric Suicide (click to see project summary)

Suicide due to major depressive disorder is a growing cause of death among adolescents and young adults. Pediatric patients treated with anti-depressants have an increased risk of suicide during the first several weeks of treatment due to lowered serotonin levels in the brain. However, early studies suggest that depressive patients respond better to treatment when also given pindolol, a high blood pressure medication. Our clinical trial will test the ability of the anti-depressant/pindolol combination therapy in lowering the risk of suicide in pediatric and young adult patients during this initial 30-day window.




mike wang photo to use 101118

Mike Wang, ScM: Repurposing Over-the-Counter Cough Medicine Dextromethorphan as a Rapid-Acting Antidepressant Without Conventional Side Effects (click to see project summary)

Conventional antidepressants that boost neurotransmitters like serotonin and dopamine prove ineffective in reversing the unexplainable increase of depression and suicide for the past 10 years (particularly in veterans and young adults). Fortunately, recent FDA trials show unprecedented treatment success with the party drug and anesthetic ketamine, which reactivates brain networks impaired by depression. Unfortunately, ketamine is impractical for addressing depression at large as it is highly intoxicating, government-restricted, and requires intensive medical monitoring. Over-the-counter cough syrup has long been recognized to act both like ketamine and first-line antidepressants, and might serve as a superior ketamine alternative with 50 years of safe and widespread use.







CA logo graphic only

The Collaborations Addressing Vulnerable Populations (CAVP) Forum is a four-tracked event dedicated to the advances being made across the healthcare landscape to support and provide treatments for patients with unmet medical needs. The CAVP Forum will highlight how drug repurposing can alleviate development costs, discuss different ways to ensure access to safe and cost-effective drugs, examine regulatory pathways and incentives targeting rare and neglected tropical diseases, and explore public–private partnerships that support the development of new treatments for vulnerable populations.

For a 20% discount code on CAVP Forum registration,


Thank you to our Sponsors!







Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*


If the link above doesn't work, please contact our Admin support at with your Full Name and Email Address to sign up!


Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Monday the 6th. Copyright 2018 Cures Within Reach.